Ethinylestradiol is beneficial for postmenopausal patients with heavily pre-treated metastatic breast cancer after prior aromatase inhibitor treatment: a prospective study

High concordance between HercepTest immunohistochemistry and ERBB2 fluorescence in situ hybridization before and after implementation of American Society of Clinical Oncology/College of American Pathology 2007 guidelines

(2012) Maria E Vergara-Lluri et al.   MODERN PATHOLOGY

Comparison of prognostic values between combined immunohistochemical score of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, Ki-67 and the corresponding gene expression score in breast cancer

(2012) Mutsuko Yamamoto-Ibusuki et al.   MODERN PATHOLOGY

High-dose estrogen as salvage hormonal therapy for highly refractory metastatic breast cancer: A retrospective chart review

(2010) Reshma L. Mahtani et al.   CLINICAL THERAPEUTICS

New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis

(2009) V. Craig Jordan et al.   BREAST

Lower-Dose vs High-Dose Oral Estradiol Therapy of Hormone Receptor–Positive, Aromatase Inhibitor–Resistant Advanced Breast Cancer

(2009) Matthew J. Ellis et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Reprint of Are all estrogens the same?

(2008) Herjan J.T. Coelingh Bennink   MATURITAS

Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer

(2008) Hirotaka Iwase   Breast Cancer